Auteur : GRECC

Psilocybin for treatment-resistant depression : fMRI-measured brain mechanisms, Robin L. Carhart-Harris et al., 2017

Psilocybin for treatment-resistant depression : fMRI-measured brain mechanisms Robin L Carhart-Harris, Leor Roseman, Mark Bolstridge, Lysia Demetriou, J Nienke Pannekoek, Matthew B Wall, Mark Tanner, Mendel Kaelen, John McGonigle, Kevin Murphy, Robert Leech, H Valerie Curran & David J Nutt Nature, Scientific Reports, 2017, 7, 13187 |1-11 Doi : 10.1038/s41598-017-13282-7   Abstract Psilocybin with psychological support is showing promise as a treatment model in psychiatry but its therapeutic mechanisms are poorly understood. Here, cerebral blood flow (CBF) and blood oxygen-level dependent (BOLD) resting-state functional connectivity (RSFC) were measured with functional magnetic resonance imaging (fMRI) before and after treatment with psilocybin (serotonin agonist) for treatment-resistant depression (TRD). [...]

Lire la suite

Un grand débat sur une politique de régulation des drogues, Fédération Addiction, publié le 19/04/2021

Un grand débat sur une politique de régulation des drogues publié le 19/04/2021  | Communiqué du 19 avril 2021 La Fédération Addiction appelle depuis longtemps à un grand débat sur la régulation des substances psychoactives tant en termes de santé que de sécurité. Le président de la République dresse le constat que « la France est devenue un pays de consommation ». La pénalisation de l’usage de drogues illégales n’a pourtant jamais été remise en cause depuis 51 ans, notre législation reste une des plus sévères et l’application des sanctions n’a cessé de se renforcer. Tout cela est parfaitement documenté par les travaux de l’OFDT et OEDT[1]. Sur la même période, prévention et réduction [...]

Lire la suite

Psilocybin Delivers ‘Remarkable’ Relief in Severe Depression, Batya Swift Yasgur, Medscape.com, 2020

Psilocybin Delivers 'Remarkable' Relief in Severe Depression Batya Swift Yasgur, MA, LSW Medscape Medical News, November 05, 2020   Psilocybin, the psychedelic compound in "magic mushrooms," rapidly improves symptoms and produces remission in as little as two sessions for patients with major depression, new research suggests. Results of a small randomized trial showed that treatment with psilocybin was associated with a greater than 50% reduction in depressive symptoms in 67% of study participants. In addition, 71% showed improvement at 4-week follow-up, with more than 50% achieving remission. "The finding that the majority of people whom we treated showed efficacy was quite a remarkable and gratifying finding [...]

Lire la suite

Psilocybin Matches SSRI for Moderate-to-Severe Depression in Phase 2 Study, Sarah Edmonds, 2021

Psilocybin Matches SSRI for Moderate-to-Severe Depression in Phase 2 Study Sarah Edmonds Medscape Medical News, April 14, 2021   The psychedelic drug psilocybin performed just as well as a widely used antidepressant in easing the symptoms of major depression, and outperformed the selective serotonin reuptake inhibitor (SSRI) on a range of secondary measures, results of a small-scale phase 2 study show. In a 6-week trial that included 59 patients with moderate-to-severe depression, there was no significant difference between the impact of high-dose psilocybin on the study's primary yardstick — the 16-item Quick Inventory of Depressive Symptomatology–Self-Report (QIDS-SR-16) — and that of selective serotonin reuptake [...]

Lire la suite

‘Magic Mushrooms’ Effective for Severe Depression, Batya Swift Yasgur, medscape.com, 2017

'Magic Mushrooms' Effective for Severe Depression Batya Swift Yasgur, MA, LSW Medscape Medical News © 2017 October 20, 2017   Psilocybin, the psychoactive compound in “magic mushrooms,” is a promising intervention for patients with treatment-resistant depression (TRD) and appears to offer a rapid, sustained effect, new research shows. Investigators led by David Nutt, MD, PhD, professor of neuropsychopharmacology, Imperial College, London, United Kingdom, collected pre- and posttreatment fMRI data on the use of psilocybin in 19 patients with severe major depression who had failed to respond to conventional treatments. The patients experience dramatic improvements in depressive symptoms 1 day following treatment; close to half met criteria for full response at 5 [...]

Lire la suite

FDA Grants Psilocybin Second Breakthrough Therapy Designation for Resistant Depression, Megan Brooks, medscape.com, 2019

FDA Grants Psilocybin Second Breakthrough Therapy Designation for Resistant Depression Megan Brooks Medscape Medical News © 2019 November 25, 2019   The US Food and Drug Administration (FDA) has granted the Usona Institute breakthrough therapy designation for psilocybin for the treatment of major depressive disorder (MDD). This marks the second time the FDA has granted breakthrough designation for psilocybin, the psychoactive ingredient in "magic mushrooms." In October 2018, Compass Pathways received the designation to test the safety and efficacy of psilocybin-assisted therapy for treatment-resistant depression, as reported by Medscape Medical News. "The results from previous studies clearly demonstrate the remarkable potential for psilocybin as a treatment in MDD patients, which Usona is [...]

Lire la suite

Clinical Evidence of Magistral Preparations Based on Medicinal Cannabis, Sara Arias et al., 2021

Clinical Evidence of Magistral Preparations Based on Medicinal Cannabis Sara Arias, Marta Leon, Diego Jaimes and Rosa-Helena Bustos Pharmaceuticals, 2021, 14, 78, 1-13. Doi :10.3390/ph14020078   Abstract : Cannabis has been widely used as a medicinal plant for millennia; however, studies related to its main components were first conducted in 1960. Subsequently, laboratories have produced new components and structures related to its active biological properties. Countries that have approved the medicinal use of cannabis impose regulations that govern its clinical and scientific use. One means of administering medicinal cannabis is via a magistral preparation that must have a medical prescription and be prepared in an establishment [...]

Lire la suite

Cannabis-Based Oral Formulations for Medical Purposes : Preparation, Quality and Stability, Francesca Baratta et al., 2021

Cannabis-Based Oral Formulations for Medical Purposes : Preparation, Quality and Stability Francesca Baratta, Marco Simiele, Irene Pignata, Lorenzo Ravetto Enri, Antonio D’Avolio, Riccardo Torta, Anna De Luca, Massimo Collino and Paola Brusa Pharmaceuticals, 2021, 14, 171, 1-13. Doi : 10.3390/ph14020171   Abstract : Current legislation in Italy provides that medical Cannabis may be administered orally or by inhalation. One of the fundamental criteria for the administration of oral formulations is that they deliver a known consistent quantity of the active ingredients to ensure uniform therapies leading to the optimisation of the risks/benefits. In 2018, our group developed an improved Cannabis oil extraction technique. The objective of [...]

Lire la suite

Cannabis sativa L. as a Natural Drug Meeting the Criteria of a Multitarget Approach to Treatment, Anna Stasiłowicz et al., 2021

Cannabis sativa L. as a Natural Drug Meeting the Criteria of a Multitarget Approach to Treatment Anna Stasiłowicz, Anna Tomala, Irma Podolak and Judyta Cielecka-Piontek International Journal of Molecular Sciences, 2021, 22, 778. Doi : 10.3390/ijms22020778 Abstract : Cannabis sativa L. turned out to be a valuable source of chemical compounds of various structures, showing pharmacological activity. The most important groups of compounds include phytocannabinoids and terpenes. The pharmacological activity of Cannabis (in epilepsy, sclerosis multiplex (SM), vomiting and nausea, pain, appetite loss, inflammatory bowel diseases (IBDs), Parkinson’s disease, Tourette’s syndrome, schizophrenia, glaucoma, and coronavirus disease 2019 (COVID-19)), which has been proven so far, results [...]

Lire la suite

Cannabidiol Adverse Effects and Toxicity, Marilyn A. Huestis et al., 2019

Cannabidiol Adverse Effects and Toxicity Marilyn A. Huestis, Renata Solimini, Simona Pichini, Roberta Pacifici, Jeremy Carlier and Francesco Paolo Busardò Current Neuropharmacology, 2019, 17, 974-989 Doi : 10.2174/1570159XI7666190603171901 Abstract : Background : Currently, there is a great interest in the potential medical use of cannabidiol (CBD), a non-intoxicating cannabinoid. Productive pharmacological research on CBD occurred in the 1970s and intensified recently with many discoveries about the endocannabinoid system. Multiple preclinical and clinical studies led to FDA-approval of Epidiolex®, a purified CBD medicine formulated for oral administration for the treatment of infantile refractory epileptic syndromes, by the US Food and Drug Administration in 2018. The World [...]

Lire la suite